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ABSTRACT
We describe a 20 month old boy with neuro-fibromatosis type 1 (NF-1) who 
presented with diencephalic syndrome due to a large hypothalamic tumour 
and developed massive necrosis after chemotherapy associated with severe 
encephalopathy.
We report this case because of rapid progression of presenting symptoms, 
the rare association with diencephalic syndrome in NF-1, chemotherapy 
induction of “tumour lysis” associated with encephalopathy, reduced toxicity 
and sustained improvement with vinblastine, the therapeutic benefit of 
tumour drainage signs of resolution of diencephalic syndrome and then 
restoration of visual movements and function associated with developmental 
recovery. The presentation of tumour in this case highlights the importance 
for parents and doctor to known and recognize the precocious symptoms, and 
justifies sharing these features as an indicator with parents and GP’s to justify 
early / urgent specialist review, particularly in the first two years of life. Early 
recognition could offer a reduced risk of brain injury.
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DISCUSSION
The delayed presentation with advanced diencephalic syndrome, blindness 
and developmental regression highlights the importance of parents and 
doctors in Primary care understanding the increased risk of tumour 
development in NF-1 patients. Early recognition of symptoms should reduce 
the risk of brain injury. Biopsy was undertaken to ascertain both histology 
prior to treatment but also to obtain tumour samples for bio-characterisation 
as new molecular markers may become the focus for new targeted therapy 
in trials and clinical practice during this child’s childhood. Primary 
treatment with chemotherapy is the current recommended approach (5) . 
INTRODUCTION
NF-1 as one of the most common genetic disorders, is associated with an increased risk of benign and malignant tumours, the commonest 
in childhood being visual pathway glioma (VPG) (1,2). Surveillance with 
clinical, ophthalmological examination or imaging in early life is performed 
to monitor for VPG, which can affect up to 20% of children with NF-1. The 
diencephalic syndrome (DS) is a rare disorder characterized by progressive 
emaciation and failure to thrive, with a normal caloric intake, due to a 
hypothalamic lesion. Its association with NF-1 has been reported rarely 
in literature (3). DS, whilst well described with hypothalamic low grade 
astrocytoma, is extremely rare in children with NF-1, and there is one case 
reported with DS presenting as disease progression in a child with NF-1 and 
VPG (4).
CASE REPORT
A 9-months old boy with a diagnosis of NF-1 (maternal history of NF-1 and 
presence of more than 6 café au lait macules) had been under surveillance 
with regular clinical and ophthalmic reviews. Normal growth, development 
and vision had been recorded. He was admitted at 20 months of age with a 5 
month history of weight loss (50nd-2nd Centile), vomiting, poor feeding, rapid 
head growth (75th-91st centile) and developmental regression. He had right 
eye ptosis with pale optic discs. Cranial MRI showed a large hypothalamic 
lesion (4.9 x 4.9 x 4.5 cm) (Figure 1) which when biopsied showed a pilocytic 
astrocytoma with pilomyxoid areas, diffuse expression of GFAP, and no 
expression of IDH-1. ATRX was intact. BRAF V600 mutation was negative. 
Chemotherapy was commenced with carboplatin vincristine regimen. After 
the first treatment he presented acutely with fever, quadriparesis, and unequal 
pupils. Cranial MRI showed an increased tumour volume and hydrocephalus 
(Figure 1), which subsequently reduced. His neurological status fluctuated over 
a 7 week period (Figure 2). Surgical tumour debulking and re-establishment of 
ventricular drainage stabilised his condition and chemotherapy was restarted 
with vinblastine 6 mg/m2 weekly, decreasing to 5 mg/m2 to reduce the chemo-
related pancytopenia. The last MRI showed a further reduction of tumour 
volume (Figure 3). Developmental progress and weight gain was re-established. 
There was a mild residual left hemi paresis. Despite persistent bilateral optic 
atrophy the child had light perception bilaterally (Figure 4). 
Figure 1) Top row: Axial T2 (left), FLAIR (centre left), post-contrast T1 (centre 
right) and ADC map (right) images showing a large hypothalamic enhancing tumour 
(arrow). At the time of presentation there was a small cystic non-enhancing area 
(dashed arrow) which showed elevated ADC, relative to the more cellular right-sided 
component of the tumour (solid arrow).Bottom row: Axial T2 (left), FLAIR (centre 
left), post-contrast T1 gradient echo volume (centre right) and ADC map images 
acquired 20 days after those in the top row. There had been marked expansion of the 
tumour, particularly of the non-enhancing component (dashed arrow). This showed 
marked ADC elevation more in keeping with necrosis than tumour progression
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associated VPG or in sporadic hypothalamic low grade glioma. This 
precipitates the suggestion that hypothalamic tumour associated with NF-
1, may justify a cautious approach to drug selection, perhaps justifying the 
use of vinblastine monotherapy in order to reduce intensity, risk of bone 
marrow and neurotoxicity whilst seeking equivalent or enhanced tumour 
control (11,12).
The imaging showed rapid expansion of the non-enhancing component 
of the tumour with associated increased diffusivity, in keeping with tumour 
necrosis rather than progression. This radiological response is frequently 
encountered following radiotherapy treatment but is extremely unusual 
after the use of chemotherapeutic agents. In distinction to the usual slow 
resolution of such findings after radiotherapy, in this case the radiological 
improvement occurred much more rapidly. In case of clinical doubt, further 
evaluation using MR perfusion (expected low relative cerebral blood volume) 
and MR spectroscopy (presence of lipid/macromolecular peak rather than 
choline elevation) would also be confirmatory.
The clinical improvement that occurred after tumour debulking and 
shunt revision was characterised by weight gain (from the 5th to above the 
50th centile), resolution of encephalopathy and progressive recovery of vision. 
Recovery of weight after treatment of DS is reported within 6 months (13-
15). The neurological recovery with improving of spasticity and recovery 
of vision was unexpected yet gratifying, fully justifying the attention of 
the multi-disciplinary brain injury rehabilitation team (16). Seizures were 
controlled with levitiracetam. Symptoms of spasticity and associated pain 
were controlled with baclofen infusions, botox injections and neuropathic 
pain drugs. Hormonal deficiencies were replaced by the endocrine team and 
rehabilitation specialists sustained programmes of movement and stimulation 
to maximise attention and daily routines. Nutritional management required 
a combination of supplementary feeding using oral NG and IV feeding 
according to requirements. 
Visual recovery came last with recovery of ophthalmoplegia and total 
blindness on initial examination. This is in contrast to studies which suggest 
that the visual loss is irreversible (17,18). There are studies where less severe 
vision loss is demonstrated to improve or at least remain stable in 72% of 
subjects after treatment (19).
CONCLUSION
This child’s serious condition at referral represented progressive brain 
injury which with early warning advice could have been avoided. At the time 
of diagnosis of NF-1, and at subsequent annual reviews, there should be a 
balanced discussion with parents, explaining that complications are rare, but 
that unusual symptoms warrant early review by a Doctor with knowledge of 
NF-1. Information on the Headsmart website (20) should be given to parents 
and sent to GP, although developmental regression has not been recognised 
as a feature for the under 5 year old group. The association between DS 
and NF-1 is rare and may be an indication of enhanced chemosensitivity 
suggesting a cautious approach to chemotherapy. Where tumour necrosis 
after chemotherapy had occurred, surgical debulking and shunt revision 
were helpful interventions. Sustaining an optimistic approach with full 
rehabilitation and detailed clinical management has allowed recovery with 
hopeful prognosis, including early signs of partial vision recovery, despite 
complete blindness at presentation.
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